State lawmakers across the country are missing important opportunities to pass and implement proven legislative solutions to prevent and fight cancer, according to a report released today by the American Cancer Society Cancer Action Network (ACS CAN). How Do You Measure Up?: A Progress Report on State Legislative Activity to Reduce Cancer Incidence and Mortality grades states on the strength of evidence-based policies that help to prevent cancer, which kills roughly 1,670 people a day nationwide, forces patients to pay nearly $4 billion in out-of-pocket expenses every year and in 2015 cost the country more than $80 billion in direct medical expenditures.
Allowing Step Therapy in Medicare Part B Could Erect Barriers to Care for Cancer for Cancer Patients
WASHINGTON, D.C. The Center for Medicare and Medicaid Services (CMS) issued guidance last night giving Medicare Advantage plans the option of applying step therapy for physician-administered and other Part B drugs, effective January 1, 2019.
A statement from American Cancer Society Cancer Action Network (ACS CAN) President Chris Hansen follows:
“ACS CAN shares the administration’s goal of lowering prescription drug costs for patients. However, the details of the policy change to allow for step therapy will be important to understand the impact on cancer patient access to lifesaving therapies.
“In some instances, utilization management tools like step therapy can create an extra hurdle for cancer patients to go through before getting the appropriate drug they need to treat their cancer. Some patients may be required to try multiple therapies before they can access the one that was prescribed by their doctor.
“It is imperative that any step-therapy process be accompanied by a speedy and easily understood appeals process to ensure patients don’t face delays to recommended treatment that could compromise the efficacy of those therapies in treating their cancer. We are pleased CMS intends to allow beneficiaries access to an appeals and exceptions process and urge them to closely monitor the extent to which beneficiaries are seeking exemptions and appeals.
“Going through cancer treatment is hard enough – cancer patients should not be forced to “fail first” on a drug that is known not to work for them before they are allowed to take the recommended treatment.”